At the last check on Friday, Sage Therapeutics Inc.’s (NASDAQ:SAGE) stock was up $0.44, moving up 2.22 percent to $20.44. The average number of shares traded per day over the past five days has been 788,520 shares. 4 times new highs have been achieved over the past 5 days, with a $0.52 gain in that time frame. In the last twenty days, the average volume was 2,588,470, while in the previous 50 days, it was 1,750,622.
Since last month, SAGE stock retreated -43.22%. Shares of the company fell to $16.51 on 08/07/23, the lowest level in the past month. A 52-week high of $59.99 was reached on 06/12/23 after having rallying from a 52-week low of $16.51. Since the beginning of this year, SAGE’s stock price has dropped by -46.39% or -$17.69, and marked a new high 17 times. However, the stock has declined by -65.92% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
SAGE stock investors should be aware that Sage Therapeutics Inc. (SAGE) stock had its last reported insider trading activity 23 days ago on Aug 09. Barrett Elizabeth, the Director of the company, purchased of 2,000 shares for $18.64 on Aug 09. It resulted in a $37,279 investment by the insider. Barrett Elizabeth added 1,000 shares at an average price of $50.50 on May 09. The insider now owns 1,000 shares following the transaction. On Feb 10, Director JONAS JEFFREY M sold 11,643 shares at $44.61 apiece. The transaction was valued at $519,413.
Valuation Metrics
The stock’s beta is 1.14. Besides these, the trailing price-to-sales (P/S) ratio of 116.77, the price-to-book (PB) ratio of 1.24.
Financial Health
In the three months ended June 29, Sage Therapeutics Inc.’s quick ratio stood at 11.00, while its current ratio was 11.00, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 92.70% percent. Based on annual data, SAGE earned $6.87 million in gross profit and brought in $7.69 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -43.70%. Return on equity (ROE) for the past 12 months was -49.80%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. SAGE’s revenue rose 39.27% to $3.29 million during the quarter, while net income inched up to $2.47 million. While analysts expected Sage Therapeutics Inc. to report -$2.55 quarterly earnings, the actual figure was -$2.68 per share, beating the consensus estimate by -5.10%. During the quarter, the company generated -$174.52 million in EBITDA. The liabilities of Sage Therapeutics Inc. were 97.91 million at the end of its most recent quarter ended June 29, and its total debt was $8.73 million. The value of shareholders’ equity is $59.88 million.
Technical Picture
This quick technical analysis looks at Sage Therapeutics Inc.’s (SAGE) price momentum. With a historical volatility rate of 13.26%, the RSI 9-day stood at 34.60% on 31 August.
With respect to its five-day moving average, the current Sage Therapeutics Inc. price is up by +2.61% percent or $0.52. At present, SAGE shares trade -43.35% below its 20-day simple moving average and -52.80% percent below its 100-day simple moving average. However, the stock is currently trading approximately -62.55% below its SMA50 and -43.13% below its SMA200.
Stochastic coefficient K was 27.82% and Stochastic coefficient D was 28.35%, while ATR was 1.08. Given the Stochastic reading of 46.43% for the 14-day period, the RSI (14) reading has been calculated as 28.43%. As of today, the MACD Oscillator reading stands at 0.15, while the 14-day reading stands at 0.04.
Analyst Ratings
Sage Therapeutics Inc. downgraded its rating on Sage Therapeutics Inc. (NASDAQ: SAGE) to a Hold in a note to investors on August 08, 2023. The analysts firm previously had a Buy rating on the stock.Sage Therapeutics Inc. (SAGE) has been rated Hold by analysts. According to 0 brokerage firms, SAGE is a sell, and 17 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Sage Therapeutics Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $22.00, the current consensus forecast for the stock is $18.00 – $79.00. Based on these forecasts, analysts predict Sage Therapeutics Inc. (SAGE) will achieve an average price target of $25.71.
